Skip to main content
Premium Trial:

Request an Annual Quote

Decipher Biosciences, Dendreon Pharmaceuticals Ink Prostate Cancer Research Deal

NEW YORK (GenomeWeb) — Decipher Biosciences — formerly GenomeDx Biosciences — announced today that it has signed an agreement to help Dendreon Pharmaceuticals identify patients who are likely to respond to its prostate cancer therapy Provenge (sipuleucel-T).

Provenge is a US Food and Drug Administration-approved autologous cellular immunotherapy. Under the terms of the deal, the Decipher assay will be used to assess the biological behavior of tumors from patients enrolled in a phase III study of Provenge. It will also evaluate tumor gene expression signatures that may be associated with Provenge response..

The Decipher assay is designed to provide a genomic assessment of tumor aggressiveness for individual patients and is derived from the San Diego-based company's Genomics Resource Information Database of urologic tumor genomic profiles.

Additional terms were not disclosed

The Scan

Billion-Dollar Diversity Initiative

The Howard Hughes Medical Institute is now accepting applications for its new $1.5 billion initiative to boost the diversity of the scientific workforce.

Biotech Co-Founder Arrested

A co-founder of a Los Angeles-based biotech company has been arrested in connection with a murder-for-hire scheme, according to Endpoint News.

Return of the Tasmanian Tiger

The Washington Post reports that a team in Australia is working to bring the thylacine back from extinction.

Nature Papers on Genome of Individual From Pompeii, CircRNA Study Best Practices, More

In Nature this week: first sequenced genome of a person from Pompeii, best practice guidelines for circRNA studies, and more.